Natixis Advisors LLC Buys 5,875 Shares of Relx Plc (NYSE:RELX)

Key Points

• Natixis Advisors LLC increased its stake in Relx Plc by 0.5% during Q1, now holding over 1.2 million shares valued at approximately $60.9 million.
• Relx announced a semi-annual dividend of $0.2634 per share, resulting in a yield of 1.7%, with the ex-dividend date set for August 8th.
• Analysts have generally rated Relx as a "Buy," with upgrades from several brokerages, though the stock recently fell by 0.3% to $51.76.

Natixis Advisors LLC lifted its stake in Relx Plc (NYSE:RELX - Free Report) by 0.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,208,467 shares of the technology company's stock after acquiring an additional 5,875 shares during the quarter. Natixis Advisors LLC owned approximately 0.07% of Relx worth $60,919,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Larson Financial Group LLC grew its holdings in Relx by 612.5% during the first quarter. Larson Financial Group LLC now owns 513 shares of the technology company's stock worth $26,000 after purchasing an additional 441 shares during the period. Golden State Wealth Management LLC boosted its holdings in shares of Relx by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 588 shares of the technology company's stock worth $30,000 after acquiring an additional 294 shares during the period. Cornerstone Planning Group LLC boosted its holdings in shares of Relx by 325.2% during the first quarter. Cornerstone Planning Group LLC now owns 693 shares of the technology company's stock worth $37,000 after acquiring an additional 530 shares during the period. Transce3nd LLC bought a new stake in shares of Relx during the fourth quarter worth approximately $40,000. Finally, Brown Brothers Harriman & Co. boosted its holdings in shares of Relx by 218.5% during the fourth quarter. Brown Brothers Harriman & Co. now owns 965 shares of the technology company's stock worth $44,000 after acquiring an additional 662 shares during the period. Institutional investors and hedge funds own 15.02% of the company's stock.

Relx Trading Down 0.6%

NYSE RELX traded down $0.30 on Friday, reaching $51.59. The company had a trading volume of 1,259,196 shares, compared to its average volume of 1,028,497. The firm has a market cap of $94.76 billion, a price-to-earnings ratio of 27.74, a P/E/G ratio of 3.38 and a beta of 0.88. Relx Plc has a fifty-two week low of $43.45 and a fifty-two week high of $56.33. The business has a 50 day moving average of $53.31 and a two-hundred day moving average of $51.53. The company has a debt-to-equity ratio of 2.55, a current ratio of 0.47 and a quick ratio of 0.42.

Relx Cuts Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, September 16th. Shareholders of record on Friday, August 8th will be issued a dividend of $0.2634 per share. This represents a yield of 170.0%. The ex-dividend date is Friday, August 8th. Relx's dividend payout ratio (DPR) is presently 65.05%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on RELX shares. Morgan Stanley reiterated an "overweight" rating on shares of Relx in a research note on Wednesday, April 16th. Wall Street Zen upgraded Relx from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy".

Relx Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.